Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Cognition Disorders in Old Age, Cognitive and Behavioral Impairment
In brief
This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period. The participants will receive the intervention for 4 weeks and followed up every 2 weeks. The primary outcome is improvement in cognitive function, while secondary outcomes include safety, tolerability, and quality of life measures. The findings may provide evidence for the potential role of L-arginine in supporting cognitive health in elderly populations.
Key facts
- Study ID
- NCT07338682
- Run by
- German University in Cairo
- People needed
- 60
- Starts
- 2025-08-27
- Expected to finish
- 2026-06-30
- Last updated by the study team
- 2026-01-21
Who can join
Age: 60 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age >60 years
- Montreal Cognitive Assessment (MoCA) test score from 10-25 (mild to moderate cognitive impairment)
You may not qualify if…
- Presence of neurodegenerative diseases (e.g.: Alzheimer's disease, Parkinson's disease, Huntington's disease, Multiple Sclerosis)
- Patients with history of L-arginine intolerance or allergy
- Patients with asthma
- Patients who recently had an acute myocardial infarction
- Patients with history of stroke within 1 yaear
- Patients who started or discontinued medications that may affect cognitive function (e.g., CNS psychotropics, antihistamines, or acetylcholinesterase inhibitors) during the study period.
- Patients who initiated or stopped antihypertensive medications during the study period.
- Patients who initiated or stopped antidiabetic medications during the study period.
- Patients who initiated or stopped antihyperlipidemic medications during the study period.
- Patients prescribed medications for depression, anxiety, or stress that may impact cognitive function
- Patients on nitrates, phosphodiesterase-5 inhibitors, potassium sparing diuretics
- Refusal to provide written informed consent
Where it is running
- Neurology Department, Al-Azhar University Hospitals — Cairo, Egypt (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.